Nine biotech companies are set to make significant advances in 2024. Aiolos Bio, focusing on treatments for respiratory and inflammatory diseases, plans its phase 2 clinical trial. Capstan Therapeutics is developing treatments with precise cell engineering. Carisma Therapeutics is developing cancer treatments. Cellarity uses AI for drug discovery. Kriya Therapeutics is backed by $600 million for gene therapy development. Maze Therapeutics uses genetics to develop precision medicines. Quotient Therapeutics uses advanced sequencing technology. ReNAgade Therapeutics, with $300 million in funding, develops RNA medicines. OrsoBio focuses on therapies for severe metabolic disorders.
A Threat-Intelligence Based Approach to Address Uncertainty in Cyber Risk Analysis and Improve Decision-Making – Wiley Online Library
Hey there, fellow Bay Area dwellers! In a world where online threats are part of daily lives, I’m sure you know that cyber risks are
